Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2002

View Archived Issues

Zonagen and Lavipharm merge in a tax-free, stock-for-stock transaction

Biovation and Micromet expand collaboration

Novartis to evaluate cardiovascular outcome benefits of Lotrel in new trial

BresaGen acquires patent rights in stem cell technology

Once-daily tomoxetine reported effective in ADHD

Beneficial effects reported for recombinant human GAA in infantile Pompe's disease

New data on ranolazine in chronic angina: the CARISA study

Raloxifene in women with increased cardiovascular risk

E.U. approval for Somavert

Ocinaplon reported effective and safer than benzodiazepines in GAD

Aciphex combination treatment approved for seven-day eradication of H. pylori

Studies show NGD-971 to be ineffective in Alzheimer's patients

Pharmacia updates Bextra label with new warnings

Roche to acquire promising portfolio of cancer drugs from Antisoma

BioPartners to use Durect technology to produce sustained-release interferon alfa

Urea-based VR1 antagonists as potential analgesic agents

Series of PDE5 inhibitors identified by Pfizer researchers

Compounds with 5-HT reuptake-inhibitory/5-HT1A receptor-antagonist activity discovered at Wyeth

New antithrombotic compounds under study at Boehringer Ingelheim

Gruenenthal and U. of Leiden describe new modulators of NMDA and adenosine metabolism

Novel p38 inhibitors synthesized by Pfizer scientists

Aventis scientists present new tubulin polymerization inhibitors

Cel-Sci enters agreement with Proxima Concepts for development of oral CEL-1000

THP and SangStat collaborate on development of humanized polyclonal antibody drugs

Antitumor activity and resistance mechanisms further characterized for XR-5944 and XR-11576

Phase I data for NB-1011 discussed at EORTC-NCI-AACR symposium

Oxi-4503 compares favorably to CA4P in antivascular and antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...